Treating obesity using glucagon-like peptide-1-directed N-methyl-D-aspartate receptor inhibition
May 20, 2024 / Obesity / GLP-1 / Syndrome Drug / Weight Loss
A study in Nature developed the drug MK-801, combining NMDA receptor antagonism and GLP-1 receptor agonism, which effectively treated obesity, hyperglycemia, and dyslipidemia in mice by reducing body weight and improving metabolic health.
How a liver-on-a-chip model of fatty liver disease could assist in preventing a global healthcare crisis
May 20, 2024 / MASH / Drug Development / MASLD
A liver-on-a-chip model has advanced understanding of fatty liver disease (MASLD) and its progression to MASH, highlighting BMP8B as a key target for anti-MASH therapeutics. This model offers accurate human-like disease representation, aiding drug development.
Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
May 20, 2024 / Obesity / Metabolic Health / Gene Therapy / Preclinical Study
Fractyl Health’s preclinical study presented at Digestive Disease Week 2024 shows that single-administration GLP-1 pancreatic gene therapy (Rejuva®) significantly reduces liver weight, liver triglycerides, total cholesterol, and LDL cholesterol in obese mice, indicating potential for profound metabolic benefits.
Canaccord maintains target on Inventiva shares amid MASH therapy potential
May 20, 2024 / MASH / FDA Approval
Canaccord Genuity maintains a Buy rating and $20 target for Inventiva shares, driven by the potential of lanifibranor for MASH therapy. Lanifibranor, showing positive Phase IIa results, could become a leading treatment for MASH, especially in combination therapies.
The microbial metabolite agmatine induces polycystic ovary syndrome in mice
May 20, 2024 / PCOS / GLP-1
A study shows that the gut microbial metabolite agmatine, produced by Bacteroides vulgatus, activates the FXR receptor, inhibiting GLP-1 secretion and inducing PCOS in mice. Treatment with the GLP-1 receptor agonist liraglutide or inhibiting agmatine production reverses PCOS.
Gout in Patients With Advanced Chronic Kidney Disease
May 20, 2024 / Kidney Disease / CKD / Gout Management
A study found that 24% of patients with advanced CKD (eGFR <60 mL/min/1.73 m2) have gout, often unmanaged, leading to increased cardiovascular and bone health issues. Improved gout management could enhance overall health in these patients.
Causal effect of blood osteocalcin on the risk of Alzheimer’s disease and the mediating role of energy metabolism
May 20, 2024 / Alzheimer’s Disease / Lipid Metabolism
A Mendelian randomization study indicates that higher blood osteocalcin levels reduce Alzheimer’s disease (AD) risk by improving glucose and lipid metabolism. This protective effect is mediated through lower fasting glucose and total cholesterol levels.
Body fat percentage beats BMI in predicting obesity-related health risks, study says
May 19, 2024 / Obesity / Metabolic Syndrome
A study in the Journal of Clinical Endocrinology & Metabolism found that body fat percentage (%BF) is more accurate than BMI for predicting obesity-related health risks. They recommend %BF thresholds for overweight (25% for men, 36% for women) and obesity (30% for men, 42% for women).
Dietary intake, obesity, and metabolic risk factors among children and adolescents in the SEACO-CH20 cross-sectional study
May 17, 2024 / Childhood Obesity / New Study / Metabolic Risk
A study in semi-rural Malaysia found that poor adherence to dietary recommendations among children and adolescents is linked to obesity and metabolic risk factors, emphasizing the need for early dietary interventions to improve long-term health outcomes.
Mortality outcomes in diabetic metabolic dysfunction-associated fatty liver disease: non-obese versus obese individuals
May 17, 2024 / Diabetes / MAFLD / Obesity / Cadiovascular Risk / Liver Disease
A study using NHANESIII data found that both obese and non-obese individuals with diabetic MAFLD have higher all-cause and cardiovascular disease mortality risks compared to non-diabetic MAFLD individuals. Screening for MAFLD should include all diabetic patients, regardless of obesity.
Study finds rise in global metabolic health risks
May 17, 2024 / Metabolic Health / Hypertension / Global Impact
The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 reports a 49.4% increase in DALYs due to metabolic risk factors from 2000 to 2021, highlighting the rising global impact of conditions like diabetes and hypertension, particularly in younger populations.
Deficiency of ADAR2 ameliorates metabolic-associated fatty liver disease via AMPK signaling pathways in obese mice
May 17, 2024 / NAFLD / Liver Disease / Insulin / Metabolism
Deficiency of ADAR2 in obese mice protects against non-alcoholic fatty liver disease (NAFLD) by improving glucose tolerance, insulin resistance, and reducing liver fat through activation of AMPK signaling pathways.
Why are men at higher diabetes, diabetes complications risk than women?
May 17, 2024 / Mens Diabetes Risk / Insulin Resistance
Men have higher risks of developing type 2 diabetes and related complications due to greater insulin resistance in abdominal fat, influenced by different fat distribution and gene expression. This highlights the need for sex-specific diabetes treatments.
Weight Loss Wonders: New Study Uncovers Surprising Benefits of the Protein Kallistatin
May 16, 2024 / Weight Loss / Obesity / Kallistatin / insulin / Metabolic Health
Weight loss increases Kallistatin levels in overweight individuals, enhancing metabolism and improving hepatic insulin sensitivity. This protein presents a promising target for treating obesity and type 2 diabetes.
Metabolic Syndrome Linked to Lower Disease-Free Survival in Breast Cancer Survivors
May 16, 2024 / Metabolic Syndrome / Cancer
Breast cancer survivors with metabolic syndrome have shorter disease-free survival, as shown in a study presented at ESMO Breast Cancer 2024, highlighting the need for metabolic screening and interventions to improve outcomes.
Gut microbiota and obesity: New study shows promising results with probiotic and prebiotic intervention
May 16, 2024 / Obesity / Weight Loss / Prebiotic Diet
A study in Scientific Reports found that a low-calorie, high-fiber diet combined with probiotics and regular physical activity improved health, body composition, and physique in obese Egyptian women, indicating the potential of gut microbiota modulation in obesity management.
Dr. Leanne Redman to lead Pennington Biomedical’s Nutrition Obesity Research Center
May 16, 2024 / Leanne Redmen / Obesity
Dr. Leanne Redman has been appointed Director of Pennington Biomedical’s Nutrition Obesity Research Center (NORC), succeeding Dr. Eric Ravussin. NORC, funded by the NIH, supports nutrition and obesity research, aiming to understand and treat obesity-related diseases.
Intermittent fasting protects against liver inflammation, liver cancer
May 16, 2024 / Liver Cancer / Fatty Liver Diease
A study by DKFZ and the University of Tubingen found that 5:2 intermittent fasting protects against liver inflammation and liver cancer in mice by enhancing beneficial metabolic changes, highlighting its potential for treating chronic liver conditions.
Number of people experiencing poor health, early death from metabolism-related risk factors has increased since 2000
May 16, 2024 / BMI / Metabolic Conditions / chronic Disease / Metabolism
The Global Burden of Disease study reveals a 49.4% increase in DALYs due to metabolism-related risk factors, including high BMI, high blood pressure, and high blood sugar, from 2000 to 2021, highlighting the growing health impact of metabolic conditions.
Investigating the Link Between Metabolism and Cancer
May 15, 2024 / Cancer / Metabolism / Insulin
Rachel Perry’s research explores how systemic metabolism impacts cancer, revealing that insulin resistance funnels glucose to tumors, thus promoting growth. Low-carb diets, exercise, and metabolic drugs show promise in reducing cancer risk and improving treatment outcomes.